

Special Issue

Advances in Antimicrobial Strategies to Control *Listeria* in Food and Clinical Settings

Message from the Guest Editor

Listeria monocytogenes is a significant foodborne pathogen known for its resilience in diverse environments and its ability to cause severe illness, particularly in immunocompromised individuals, pregnant women, and the elderly. *L. monocytogenes* is frequently found in ready-to-eat foods, dairy products, and processed meats. Contamination of these foods can lead to outbreaks of listeriosis, a serious infection that can result in severe health complications and even death. This Special Issue will explore the latest innovations in antimicrobial approaches to manage and mitigate the risks associated with this persistent pathogen. This Special Issue will cover a wide array of topics, including but not limited to the following:

- Natural and synthetic antimicrobial agents
- Development and utilization of probiotic strains
- Biofilms in *Listeria* and anti-biofilm strategies
- Mechanisms of resistance
- Regulatory and safety considerations

Guest Editor

Dr. José Ramos-Vivas

Research Group on Foods, Nutritional Biochemistry and Health,
Universidad Europea del Atlántico, Santander, Spain

Deadline for manuscript submissions

28 February 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/229054

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)